Immix Biopharma, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 191.9K | $1.75M | 0.00% | Added+97.1% | 2026-03-31 |
| TRowePrice | fundamental | 415.0K | $3.78K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -0.21 | -0.18 | +13.25% |
| 2026-03-25 | -0.16 | -0.28 | -75.00% |
| 2025-11-07 | -0.19 | -0.24 | -26.32% |
| 2025-08-08 | -0.16 | -0.22 | -37.50% |
| 2025-05-08 | -0.23 | -0.15 | +34.78% |
| 2025-03-25 | -0.25 | -0.15 | +40.00% |
| 2024-11-12 | -0.16 | -0.24 | -50.00% |
| 2024-08-12 | -0.21 | -0.15 | +28.57% |
| 2024-05-09 | -0.23 | -0.22 | +4.35% |
| 2024-03-29 | -0.23 | -0.24 | -4.35% |
| 2023-11-13 | -0.23 | -0.23 | — |
| 2023-08-11 | -0.17 | -0.24 | -41.18% |
| 2023-05-12 | -0.14 | -0.18 | -28.57% |
| 2023-03-27 | -0.22 | -0.27 | -22.73% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IMMX | -3.23% | +10.43% | +72.08% | +284.62% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.19% | +15.07% | +75.53% | +271.93% |